In 2007, Rodolphe Barrangou, a former Chairman of the Board of Directors of Caribou Biosciences and current scientific advisor, led the group that characterized CRISPR systems as a form of
prokaryotic adaptive immunity that provides a critical line of defense against invading phages, plasmids, and environmental nucleic acids.